NEW YORK, Sept 6 - Applied Biosystems (NYSE: PEB) said on Wednesday it had agreed to make a $3 million equity investment in software developer Genomica.
The companies also signed an agreement under which Genomica will license its genetic-analysis object model to Applied Biosystems.
The object model will allow Applied Biosystems to store genotyping results garnered from its various instruments in a common Oracle database. Genomica's bioinformatics software products could then be used to access the genotyping results for scientific analysis.
" The object model enhances the capability to pool data,” said Jay Rhodes, a spokesman for Applied Biosystems. “The enhanced Applied Biosystems system is what gets sold.”Rhodes declined to disclose the terms of the licensing agreement or to say what percent of Genomica’s equity Applied Biosystems will own following the deal.
A spokesperson for Genomica was not immediately available for comment.
Based in Foster City, Calif., Applied Biosystems makes instruments, reagents and software used to discover new pharmaceuticals and analyze criminal evidence.
Genomica of Boulder, Colo., develops software products used by pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process. The company’s customers include AstraZeneca (NYSE: AZN), GlaxoWellcome (NYSE:GLX), and the National Cancer Institute.
Genomica and Applied Biosystems previously partnered to develop software products to be used with Applied Biosystems’ hardware.